LRRK2 and Parkinson disease: In this study, we revealed that transgenic expression of a G2019S mutant, compared to wild-type LRRK2, downregulated the transcription level of several proteins in the Hippo signaling pathway (Figure 3), which may suggest that the G2019S mutant advances PD pathological progress by dysregulating the Hippo signaling pathway.